talampanel Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Talampanel is a drug which has been investigated for the treatment of epilepsy, malignant gliomas, and amyotrophic lateral sclerosis (ALS).   Wikipedia

Chemistry

  • SMILES: CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3
  • InChIKey: JACAAXNEHGBPOQ-LLVKDONJSA-N
  • Mol. Mass: 337.38
  • ALogP: 2.54
  • ChEMBL Molecule:
    talampanel  
More Chemistry

Pharmacology

Alternative names

1-(4'-aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5h-2,3-benzodiazepine | 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7h-1,3-dioxolo(4,5-h)benzodiazepine | gyki 53405 | gyki-53405 | gyki53773 | gyki 53773 | gyki-53773 | ly300164 | ly 300164 | ly-300164 | talampanel

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Astrocytoma (Phase 2)

Brain Neoplasms (Phase 2)

Dyskinesias (Phase 2)

Epilepsy (Phase 2)

Glioblastoma (Phase 2)

Healthy Volunteers (Phase 2)

Movement Disorders (Phase 1/Phase 2)

Oligodendroglioma (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue